LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,092
تعداد مقالات10,022
تعداد مشاهده مقاله27,218,499
تعداد دریافت فایل اصل مقاله7,471,672
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, 20(4), 466-472. doi: 10.22034/iji.2023.99254.2629
Miao Zhu; Jun Zhang; Qingqing Shi; Xing Sun; Haibo Wang; Mei Sun; Yanqing Liu. "Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report". سامانه مدیریت نشریات علمی, 20, 4, 1402, 466-472. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. (1402). 'Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report', سامانه مدیریت نشریات علمی, 20(4), pp. 466-472. doi: 10.22034/iji.2023.99254.2629
Zhu, Miao, Zhang, Jun, Shi, Qingqing, Sun, Xing, Wang, Haibo, Sun, Mei, Liu, Yanqing. Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report. سامانه مدیریت نشریات علمی, 1402; 20(4): 466-472. doi: 10.22034/iji.2023.99254.2629

Rescue of HLH with T and B Lymphocyte Involvement Due to Epstein-Barr Virus by PD-1 Inhibitor/Ruxolitinib and Rituximab Combination Regimens: A Case Report

Iranian Journal of Immunology
مقاله 8، دوره 20، شماره 4، اسفند 2023، صفحه 466-472    اصل مقاله (1.17 M)
نوع مقاله: Case Report
شناسه دیجیتال (DOI): 10.22034/iji.2023.99254.2629
نویسندگان
Miao Zhu1، 2؛ Jun Zhang2؛ Qingqing Shi2؛ Xing Sun2؛ Haibo Wang1؛ Mei Sun2؛ Yanqing Liu* 1
1The Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225000, Jiangsu, China.
2Clinical Medical College, Yangzhou University, Yangzhou 225001, China.
چکیده
Hemophagocytic lymphohistiocytosis (HLH) is a fatal clinical syndrome. The most common cause of secondary HLH is Epstein-Barr virus (EBV) infection. EBV-HLH is a common clinical disease with high mortality, easy relapse, and poor prognosis. Therefore, treating EBV-HLH with T and B lymphocyte involvement is challenging, and selecting an appropriate treatment regimen is critical. Moreover, research on how to evaluate the recurrence index after remission is scarce. In this study, we reported a case of EBV-HLH successfully treated with programmed cell death protein-1 (PD-1) inhibitor in combination with rituximab. The regimen had a good curative effect, and we successfully detected the trend of early recurrence. Our findings indicated that PD-1 inhibitor in combination with rituximab may help to treat EBV-HLH and maintain EBV-infected T and B whole-line lymphocytes.
کلیدواژه‌ها
CD20 Monoclonal Antibody؛ Epstein-Barr Virus؛ Hemophagocytic Lymphohistiocytosis؛ Programmed Cell Death Protein-1؛ Salvage Therapy
سایر فایل های مرتبط با مقاله
مراجع
  1. Imashuku S, Morimoto A, Ishii E. Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr. 2021;110(10):2729-2736.
  2. Maakaroun NR, Moanna A, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93-105.
  3. Mottaghipisheh H, Kalantar K, Amanati A, et al. Comparison of the clinical features and outcome of children with hemophagocytic lymphohistiocytosis (HLH) secondary to visceral leishmaniasis and primary HLH: a single-center study. BMC Infect Dis. 2021;21(1):732.
  4. Cui X, Snapper CM. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases. Front Immunol. 2021;12:734471.
  5. Ressing ME, van Gent M, Gram AM, et al. Immune Evasion by Epstein-Barr Virus. Curr Top Microbiol Immunol. 2015;391:355-81.
  6. JankaGE, LehmbergK. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematology Am Soc Hematol Educ Program, 2013, 2013:605-611. 
  7. Maakaroun NR, Moanna A, Jacob JT. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93-105.
  8. Ohga S, Nomura A, Hara T. Immunological aspects of Epstein-Barr virus infection. Crit Rev Oncol Hematol. 2002;44(3):203-15.
  9. Diao B, Huang X, Guo S,et al. MAGT1-mediated disturbance of Mg2+ homeostasis lead to exhausted of HBV-infected NK and CD8+ T cells. Sci Rep. 2017;7(1):13594.
  10. Elmore JP, McGee MC, Nidetz NF,et al. Tuning T helper cell differentiation by ITK. Biochem Soc Trans. 2020;48(1):179–185.
  11. Ghosh S, Bienemann K, Borkhardt A. Interleukin-2-inducible T-cell kinase (ITK) deficiency - clinical and molecular aspects. J Clin Immunol. 2014;34(8):892–9.
  12. Moore EK, Strazza M, Mor A. Combination Approaches to Target PD-1 Signaling in Cancer. Front Immunol. 2022;13:927265.
  13. Henter JI, Aricò M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol. 1997;28(5):342-7.
  14. J Henter , Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-31.
  15. Bergsten E, Horne A, Aricó M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728-2738.
  16. Johnson TS, Terrell CE, Millen SH, et al. Etoposide selectively ablates activated T cells to control the immunoregulatory disorder hemophagocytic lymphohistiocytosis. J Immunol. 2014;192(1):84-91.
  17. Keenan C, Nichols KE, Albeituni S. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. Front Immunol. 2021;12:614704.
  18. Wang H, Gu J, Liang X, et al. Low dose ruxolitinib plus HLH-94 protocol: A potential choice for secondary HLH. Semin Hematol. 2020;57(1):26-30.
  19. Zhang Q, Wei A, Ma HH, et al. A pilot study of ruxolitinib as a front-line therapy for 12 children with secondary hemophagocytic lymphohistiocytosis. Haematologica. 2021;106(7):1892-1901.
  20. Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186-92.
  21. Lai W, Wang Y, Wang J, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center. Hematology. 2018;23(10):810-816.
  22. Chatterjee B, Deng Y, Holler A, et al. CD8+ T cells retain protective functions despite sustained inhibitory receptor expression during Epstein-Barr virus infection in vivo. PLoS Pathog. 2019;15(5):e1007748.
  23. Kim ST, Cristescu R, Bass AJ, et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449-1458.
  24. Meng GQ, Wang JS, Wang YN, et al. Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. Int Immunopharmacol. 2021;96:107606.
  25. Latour S, Fischer A. Signaling pathways involved in the T-cell-mediated immunity against Epstein-Barr virus: Lessons from genetic diseases. Immunol Rev. 2019;291(1):174-189.
  26. Liu P , Pan X , Chen C, et al. Nivolumab treatment for relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistocytosis in adults. Blood. 2020;135 (11):826–833.
  27. Young LS, Yap LF, Murray PG. Epstein-Barr virus: more than 50 years old and still providing surprises. Nat Rev Cancer. 2016;16(12):789-802.
  28. Kerr JR. Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors. J Clin Pathol. 2019;72(10):651-658.
  29. Fournier B, Boutboul D, Latour S, et al. Rapid identification and characterization of infected cells in blood during chronic active Epstein-Barr virus infection. J Exp Med. 2020;217(11):e20192262.
  30. Shokripour M, Mokhtari M, Samizadeh B. Association of soluble interleukin-2 receptor alpha with laboratory parameters and clinical findings of hemophagocytic lymphohistiocytosis patients: The first report from South of Iran. J Educ Health Promot. 2020;9:48.
آمار
تعداد مشاهده مقاله: 633
تعداد دریافت فایل اصل مقاله: 373


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب